LXS196X
Total Payments
$197,393
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $99,537 | 1 | 0 |
| 2018 | $97,856 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $197,393 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF LXS196 AN ORAL PROTEIN KINASE C INHIBITOR IN PATIENTS WITH METASTATIC UVEAL MELANOMA | Novartis Pharmaceuticals Corporation | $197,393 | 0 |
Top Doctors Receiving Payments for LXS196X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $197,393 | 2 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $197,393
Product Information
- Type Drug
- Total Payments $197,393
- Total Doctors 0
- Transactions 2
About LXS196X
LXS196X is a drug associated with $197,393 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2019. In 2019, $99,537 was paid across 1 transactions to 0 doctors.
The most common payment nature for LXS196X is "Unspecified" ($197,393, 100.0% of total).
LXS196X is associated with 1 research study, including "A PHASE I MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF LXS196 AN ORAL PROTEIN KINASE C INHIBITOR IN PATIENTS WITH METASTATIC UVEAL MELANOMA" ($197,393).